Novartis Drug Receives Clearance

PennyStockPickReport.com is pleased to alert investors of stocks on the move. Sign Up for Free Stock Alerts

Swiss drug manufacturer Novartis AG (NYSE: NVS) recently publicized that the U.S. Food and Drug Administration has approved Tekturna HCT as initial treatment in patients unlikely to achieve their blood pressure goal with a single agent.

"Up to 85% of patients will need more than one medication to reach their blood pressure goals," said Alan Gradman, MD, Cardiologist at The Western Pennsylvania Hospital and Professor of Medicine at Temple University. "This approval gives doctors the opportunity to aggressively treat their patients with a single-pill combination of the only approved drug, Tekturna, that works by directly targeting renin and decreasing the activity of the renin angiotensin aldosterone system (RAAS) and, HCTZ, a diuretic. This results in more significant blood pressure reductions, compared to taking either drug alone."

Sign Up for Penny Stock Pick Report’s Free Small Cap Newsletter. To subscribe please enter your email address in the frame at the bottom of this page or visit us at our website.

Subscribe at the bottom of this page.

About Us

Penny Stock Pick Report is a leading stock web site that provides free stock alerts on stocks that are poised to make big gains. We also track small cap companies that could be on the brink of a massive breakout. To feature a company on our web site please contact us at the email listed below.

Penny Stock Pick Report is an independent electronic publication that provides information on selected publicly traded companies. This publication is not a registered investment advisor or broker-dealer. Our affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above. View our full disclaimer.